Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeting Hepatocellular Carcinoma using Vd1 gamma delta T cells engineered with a DAP12-based chimeric receptor

FY 2022-23

Summary
Liver cancer is one of the leading causes of cancer-related deaths worldwide, with Hepatocellular Carcinoma being the most common type. With limited treatments available for advanced-stage patients, one promising approach is adoptive cell transfer (ACT), where a patient's own immune cells are removed, modified to kill cancer better, and infused back into them. An example of ACT is CAR T-cell therapy, where immune cells known as T cells are modified with genes that allow them to express a Chimeric Antigen Receptor (CAR), a tool T cells can use to target proteins on cancer. However, using one's own cells can be time-consuming and expensive, as cell products must be personalized for every person so that the body does not reject the products thinking they are foreign cells. Additionally, CARs can be associated with Cytokine Release syndrome (CRS), an inflammatory condition that can have severe toxic side effects. Therefore, I propose an alternative approach using a rare, tissue-bound subset of T cells known as Gamma Delta (GD) T cells in ACT for HCC treatment. GD T cells do not need to come from the patient themselves, meaning they can be mass manufactured and readily available when someone needs them. Additionally, instead of a CAR, I propose modifying these GD T cells with genes that code for tools that naturally exist on other immune cells, such as DAP12, which is an activation protein. To accomplish these goals, I will begin by collecting cancerous tissue from HCC patients in order to determine what proteins to target. Then, I will build CAR-like designs composed of other natural immune receptors incorporating DAP12 to see which design offers the highest killing ability, grows the fastest, and produces the right molecules that would help fight cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486272
Name
Hilal Arwa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Hepatocellular Carcinoma using Vd1 gamma delta T cells engineered with a DAP12-based chimeric receptor
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antitumour Immunity; Cancer; Gamma Delta T Cells; Hepatocellular Carcinoma; Immunoreceptor; Immunotherapy
Abstract
Liver cancer is one of the leading causes of cancer-related deaths worldwide, with Hepatocellular Carcinoma being the most common type. With limited treatments available for advanced-stage patients, one promising approach is adoptive cell transfer (ACT), where a patient's own immune cells are removed, modified to kill cancer better, and infused back into them. An example of ACT is CAR T-cell therapy, where immune cells known as T cells are modified with genes that allow them to express a Chimeric Antigen Receptor (CAR), a tool T cells can use to target proteins on cancer. However, using one's own cells can be time-consuming and expensive, as cell products must be personalized for every person so that the body does not reject the products thinking they are foreign cells. Additionally, CARs can be associated with Cytokine Release syndrome (CRS), an inflammatory condition that can have severe toxic side effects. Therefore, I propose an alternative approach using a rare, tissue-bound subset of T cells known as Gamma Delta (GD) T cells in ACT for HCC treatment. GD T cells do not need to come from the patient themselves, meaning they can be mass manufactured and readily available when someone needs them. Additionally, instead of a CAR, I propose modifying these GD T cells with genes that code for tools that naturally exist on other immune cells, such as DAP12, which is an activation protein. To accomplish these goals, I will begin by collecting cancerous tissue from HCC patients in order to determine what proteins to target. Then, I will build CAR-like designs composed of other natural immune receptors incorporating DAP12 to see which design offers the highest killing ability, grows the fastest, and produces the right molecules that would help fight cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hilal, Arwa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~